Last reviewed · How we verify
Aricept® Evess
Aricept Evess is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain.
Aricept Evess is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain. Used for Alzheimer's disease.
At a glance
| Generic name | Aricept® Evess |
|---|---|
| Sponsor | Pfizer |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
This increase in acetylcholine helps to improve cognitive function in patients with Alzheimer's disease. By inhibiting the breakdown of acetylcholine, Aricept Evess allows for a greater amount of this neurotransmitter to be available for synaptic transmission, which can help to improve memory and cognitive function.
Approved indications
- Alzheimer's disease
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aricept® Evess CI brief — competitive landscape report
- Aricept® Evess updates RSS · CI watch RSS
- Pfizer portfolio CI